Skip to Main Content
Izidore Lossos

Izidore Lossos, M.D.

Department:

Medicine

Division:

Hematology

Izidore Lossos

Contact

Lab: 305-243-4785
Research/Lab Website

Roles

  • Professor
  • Chief, Lymphoma Section

  • Biography

    Izidore Lossos, M.D., is a Professor of Clinical Medicine and Director of the Lymphoma Program at Sylvester Comprehensive Cancer Center, where he holds an endowed chair. He earned his medical degree from Hadassah School of Medicine at Hebrew University in Jerusalem and completed his residency and fellowship in hematology at Hadassah University Hospital, followed by a postdoctoral fellowship at Stanford University. Dr. Lossos’ research focuses on lymphoma pathogenesis, molecular prognostic markers, and novel therapies. He has authored more than 365 publications and has received multiple awards, including the Celgene Young Investigator Award (2007) and the Sylvester Outstanding Cancer Research Award (2012). He is a national and International expert in lymphoma.

  • Education & Training

    Education

    • 1987
      Hadassah Medical School, Hebrew University, Jerusalem, Israel
      MD, Internal Medicine/Hematology

    Post Graduate Training

    • 2002
      Stanford University Medical Center, Stanford, California
      Other
    • 2001
      Stanford University Medical Center, Stanford, California
      Post-Doctoral Fellowship, Oncology
    • 1997
      Hadassah University Hospital, Jerusalem, Israel
      Fellowship, Hematology
    • 1995
      Hadassah University Hospital, Jerusalem, Israel
      Residency, Internal Medicine

    Licensures and Certifications

    • Israeli Board Certification, Hematology/ permanent

    • Israeli Board Certification, Internal Medicine/ permanent

    • ECFMG

  • Honors & Awards

      Loading...

      No result found

    • Research Interests

      The laboratory is investigating pathogenesis of different subtypes of non-Hodgkin's lymphomas as well as novel therapeutic approaches. Specific interests are in: 1) Function of the HGAL gene in lymphoma dissemination and BCR signaling; 2) Role of LMO2 protein in pathogenesis of DLBCL; 3) Alterations in DNA repair mechanisms in lymphoma; 4) pathogenesis of orbital marginal zone lymphomas; 5) Function and targeting of PRMT5 protein in DLBCL.

    • Publications

      Loading...

      No result found

        Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.

      • Copyrights & Patents

        “CD20-IL-21 fusokine for treatment of lymphoma and other diseases”

        240641292288, Patent

        “Composition and methods for treatment lymphoma and lymphoproliferative disorders with PARP1 inhibitors”

        240640845824, Patent

        “HG-6-64-1 and MAPK interruption for the treatment of DLBCL and other lymphomas”

        240641329152, Patent

      • Professional Activities

          Loading...

          No result found

        Articles & News

        Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.

        Clinical Trials

        Viewing 0 of 18 clinical trials.